The 2C9*3 and 2C9*2 polymorphisms of cytochrome P-450 CYP2C9 are associated with hypersensitivity to warfarin and bleeding. The effect of these polymorphisms on sensitivity to acenocoumarol is unknown. Three groups of patients, with low, medium, or high acenocoumarol-dose requirements, were studied. Age influenced the acenocoumarol sensitivity. Bearing the 2C9*3 allele was associated with the n...

The anticoagulant warfarin has >30 million prescriptions per year in the United States. Doses can vary 20-fold between patients, and incorrect dosing can result in serious adverse events. Variation in warfarin pharmacokinetic and pharmacodynamic genes, such as CYP2C9 and VKORC1, do not fully explain the dose variability in African Americans. To identify additional genetic contributors to warfar...

INTRODUCTION Chronic hepatitis C is a leading cause of severe liver disease. Protease inhibitors used to treat these patients are known to have many drug interactions, although there is limited data available between boceprevir and warfarin. This case report is the first in vivo drug interaction reported in the literature. CASE PRESENTATION A 73-year-old African American man was diagnosed wit...

Unprovoked venous thromboembolism (VTE) warrants anticoagulant therapy for a brief period of weeks to months. After it is discontinued, the risk of recurrent VTE remains high. Long-term warfarin therapy is highly effective in preventing recurrence, but it has an increased risk of bleeding, and the monitoring requirements make it inconvenient and costly for patients. Low-dose aspirin is a propos...

BACKGROUND AND PURPOSE The once-daily oral factor Xa inhibitor, edoxaban, is as effective as warfarin in preventing stroke and systemic embolism while decreasing bleeding in a phase III trial of patients with atrial fibrillation at moderate-high stroke risk. Limited data regarding cerebrovascular events with edoxaban were reported previously. METHODS We analyzed the subtypes of cerebrovascula...

BACKGROUND Warfarin is the most widely prescribed anticoagulant for the prevention and treatment of thromboembolic events. Although highly effective, the use of warfarin is limited by a narrow therapeutic range combined with a more than ten-fold difference in the dose required for adequate anticoagulation in adults. An optimal dose that leads to a favourable balance between the wanted antithrom...

AIM To determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. MATERIALS & METHODS We investigated two Turkish warfarin-treated cohorts: patients with no history of hemorrhagic or thromboembolic event and patients with major and life-threat...

Thromb Haemost 2008; 100: 175–176 More than 60 years after its successful introduction for the prevention of thromboembolic events, the coumarin anticoagulant warfarin is still one of the most frequently prescribed cardiovascular drugs. The recently conducted Active W study once again established its therapeutic superiority over even a combination of antiplatelet drugs for the prevention of str...

Warfarin is the most widely used oral anticoagulant for the treatment of thromboembolic disorders and for stroke prophylaxis. Warfarin is a problematic drug because it exhibits large interindividual variation in the required therapeutic dose, has a narrow therapeutic range, and shows multiple food and drug interactions. Its anticoagulant effect is monitored by measuring the international normal...

The question of whether or not combination antithrombotic therapy is beneficial in terms of a reduction in fatal and non-fatal vascular events in atrial fibrillation (AF) is an important question which essentially remains unanswered. Original randomised controlled trials in AF patients examining the efficacy of combination oral anticoagulant (OAC) and antiplatelet therapy for stroke prevention ...